Kazia Therapeutics

Kazia (Nasdaq: KZIA) is a clinical-stage oncology company focused on high-need cancers of the central nervous system and select aggressive solid tumors.

[Kazia Therapeutics @KaziaTx]

📣 @KaziaTX announced a provisional patent filing for a novel strategy to help prevent metastatic recurrence in high-risk early-stage #TNBC. New data suggest #paxalisib may reduce residual disease and metastatic spread. More here: https://t.co/i6hv4KK8j6
$KZIA #BreastCancer

[Kazia Therapeutics @KaziaTx]

📣 @KaziaTX announced a provisional patent filing for a novel strategy to help prevent metastatic recurrence in high-risk early-stage #TNBC. New data suggest #paxalisib may reduce residual disease and metastatic spread.
$KZIA #BreastCancer #Oncology #Innovation #DrugDevelopment

[Kazia Therapeutics @KaziaTx]

@KaziaTx is proud to share that Chief Scientific Officer, Dr. Sudha Rao, has been named in @TheCairnsPost as one of the 60 most powerful health figures behind Queensland's $33 billion health system. More here: https://t.co/qAKpK7ybxL

[Kazia Therapeutics @KaziaTx]

@Kaziatx ($KZIA)  is pleased to welcome James Levine as Chief Financial Officer. James brings more than 20 years’ experience across executive and financial leadership at listed biotech companies. More here: https://t.co/ojcS5RLvLm
#biotechleadership $KZIA

[Kazia Therapeutics @KaziaTx]

@KaziaTx ($KZIA) announces the planned expansion of Phase 1b clinical trial, evaluating lead asset paxalisib in advanced breast cancer, from 12 to 36 patients. Expansion follows encouraging safety & tolerability data. More here: https://t.co/vyqMlKWfif #breastcancer #paxalisib

[Kazia Therapeutics @KaziaTx]

Announcement: 📣 @KaziaTx has appointed Dr. Sudha Rao as Chief Scientific Officer, strengthening its leadership as it advances a next-generation oncology platform targeted towards cancers with significant unmet need. Read more here: https://t.co/iMsCopvVsM #PI3kmTOR #paxalisib

[Kazia Therapeutics @KaziaTx]

@KaziaTx has expanded its oncology platform with the in-licensing of a first-in-class SETDB1-targeted epigenetic drug discovery and development platform from @QIMRB_Institute. More here: https://t.co/7JLb2nATAS #immunotherapy #oncology

[Kazia Therapeutics @KaziaTx]

Announcement 📣 @KaziaTx is pleased to report a $50M securities purchase agreement with institutional healthcare investors for a private placement of equities securities (PIPE). More here: https://t.co/nXCXG221IF

#paxalisib #oncology #PIPEfunding

[Kazia Therapeutics @KaziaTx]

@KaziaTX is pleased to announce a collaboration and in-licensing agreement with @QIMRB_Institute for NDL2, a first-in-class PD-L1 protein degrader. Program aims to overcome resistance to current #immunotherapies in #cancers.
Read more: https://t.co/RXZmzOtmnf

[Kazia Therapeutics @KaziaTx]

🚨 NEW RESEARCH: @KaziaTx reports monotherapy ex vivo results for paxalisib achieved COMPLETE (100%) disruption of large circulating tumour cell (CTC) clusters ex vivo in Stage IV HER2+ breast cancer. 🔗 https://t.co/ZHRvBHPsUQ
#BreastCancer #Oncology

[Kazia Therapeutics @KaziaTx]

@KaziaTx announces a $2M private placement at a 5% premium to market – a strong show of confidence from institutional investors. Funds will support the clinical development of #paxalisib, EVT801, and key upcoming #breastcancer trial milestones. More here: https://t.co/SsDYlgmnc9

[Kazia Therapeutics @KaziaTx]

@KaziaTx is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®) & standard chemotherapy after completing Cycle 1 of dosing.
https://t.co/Q9mYOPGT9y

#breastcancer #paxalisib

[Kazia Therapeutics @KaziaTx]

New video from @QIMR_Berghofer shows how dual PI3K/mTOR inhibitor #paxalisib may resensitize immuno‑resistant metastatic breast cancers.

Promising preclinical synergy with checkpoint blockers—see lead researchers explain below👇

https://t.co/kZsmIXT83z

[Kazia Therapeutics @KaziaTx]

New breast cancer hope
@QIMRB_Institute research in collaboration with @KaziaTx has found that combining #paxalisib with immunotherapy shows promise in fighting triple negative breast cancer, overcoming treatment resistance & preventing cancer cell spread https://t.co/65wisNNbYM

[Kazia Therapeutics @KaziaTx]

@KaziaTx is pleased to announce 1st patient dosing in a Phase 1b trial of #paxalisib in advanced #breastcancer. Trial to assess paxalisib in combo with established immunotherapies and standard of care chemo to improve patient outcomes. More: https://t.co/DYbBPq5OQq

[Kazia Therapeutics @KaziaTx]

We’re excited to share that Professor Sudha Rao from @QIMRB_Institute will be a keynote speaker at the “Herston Breast Cancer Research Network” event, hosted by @UQ_News at their Herston Campus.
📅 Date: June 12
⏰ Time: 2:00 - 4:30 PM
📍 Location: UQCCR Auditorium
#BreastCancer

[Kazia Therapeutics @KaziaTx]

@KaziaTx is pleased to announce a grant awarded by the @MichaelJFoxOrg to fund the research investigating the therapeutic potential of #paxalisib as a treatment for Parkinson’s Disease in collaboration with @Hujimed. More: https://t.co/pEbmdo5yVn

$KZIA #Parkinsons

[Kazia Therapeutics @KaziaTx]

@KaziaTx is pleased to share an episode featuring $KZIA CEO and Prof Sudha Rao at @QIMRB_Institute, where they discuss the potential of treating advanced breast cancer with our lead drug candidate #paxalisib.🎧 Listen now: https://t.co/pfR6ur3fsu
#TNBC #oncology

[Kazia Therapeutics @KaziaTx]

As seen on @SkyNewsAust, there is an urgent unmet treatment need for advanced breast cancer patients. A new clinical trial by @KaziaTx explores treatment using #paxalisib in combination with immunotherapy. More: https://t.co/2soc0ZXjO1 $KZIA

[Kazia Therapeutics @KaziaTx]

@KaziaTx is pleased to announce the launch of a Phase 1b clinical trial, evaluating the safety and efficacy of #paxalisib in combination with #immunotherapy in advanced breast cancer patients. More: https://t.co/lLoaNdmngF.